Repligen Corporation (NASDAQ:RGEN) Stock Has Consensus Price Target of $168.57 According to Brokerages

Shares of Repligen Corporation (NASDAQ:RGEN) have earned a consensus recommendation of “Moderate Buy” from the eighteen ratings firms that are presently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $168.57.

Several equities analysts have issued reports on RGEN shares. UBS Group restated a “buy” rating on shares of Repligen in a research note on Tuesday. Evercore reiterated an “outperform” rating and set a $160.00 target price on shares of Repligen in a research report on Monday, July 6th. JPMorgan Chase & Co. boosted their target price on Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Citigroup raised Repligen to a “buy” rating in a research report on Tuesday, July 7th. Finally, Wells Fargo & Company lifted their price target on Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a research report on Thursday, July 30th.

Repligen Stock Performance

Shares of RGEN opened at $177.23 on Tuesday. The stock has a 50 day moving average price of $169.38 and a 200 day moving average price of $141.03. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $10.00 billion, a price-to-earnings ratio of 242.78, a price-to-earnings-growth ratio of 3.51 and a beta of 1.08. Repligen has a 52-week low of $100.99 and a 52-week high of $198.87.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.45 by $0.09. The company had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The firm’s revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Research analysts predict that Repligen will post 2.06 EPS for the current fiscal year.

Hedge Funds Weigh In On Repligen

Hedge funds have recently modified their holdings of the business. ABS Investment Management LLC purchased a new stake in shares of Repligen during the second quarter worth approximately $191,016,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Repligen during the second quarter worth $52,000. Trust Co. of Vermont purchased a new position in Repligen in the 2nd quarter valued at $71,000. Harbor Investment Advisory LLC grew its position in Repligen by 198.9% in the 2nd quarter. Harbor Investment Advisory LLC now owns 523 shares of the biotechnology company’s stock valued at $71,000 after buying an additional 348 shares during the last quarter. Finally, Allworth Financial LP acquired a new position in Repligen in the 2nd quarter valued at $71,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation (NASDAQ:RGEN) develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to produce biological drugs, including monoclonal antibodies, recombinant proteins, vaccines and cell and gene therapies. Its products are used throughout the manufacturing process, from laboratory and process development through commercial-scale production.

The company’s portfolio includes chromatography products and protein A ligands and resins, filtration and fluid-management systems, single-use technologies, process analytics and other consumables and equipment.